Mangoceuticals, Inc.
MGRX
$0.34
$0.012.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 456.00K | 466.80K | 516.00K | 511.10K | 615.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 456.00K | 466.80K | 516.00K | 511.10K | 615.90K |
| Cost of Revenue | 205.60K | 183.80K | 201.20K | 216.40K | 235.90K |
| Gross Profit | 250.40K | 283.00K | 314.80K | 294.70K | 380.00K |
| SG&A Expenses | 16.72M | 18.05M | 12.08M | 9.02M | 7.90M |
| Depreciation & Amortization | 1.12M | 721.50K | 721.50K | 721.50K | 721.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.05M | 18.96M | 13.00M | 9.96M | 8.86M |
| Operating Income | -17.59M | -18.49M | -12.48M | -9.45M | -8.24M |
| Income Before Tax | -20.64M | -19.82M | -14.20M | -11.18M | -8.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.64 | -19.82 | -14.20 | -11.18 | -8.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 500.00 | 900.00 | 800.00 | 1.10K | 1.00K |
| Net Income | -20.64M | -19.82M | -14.20M | -11.18M | -8.71M |
| EBIT | -17.59M | -18.49M | -12.48M | -9.45M | -8.24M |
| EBITDA | -15.87M | -16.49M | -10.51M | -8.28M | -7.48M |
| EPS Basic | -2.50 | -3.03 | -3.48 | -4.31 | -4.76 |
| Normalized Basic EPS | -1.47 | -1.87 | -2.07 | -2.60 | -2.88 |
| EPS Diluted | -2.50 | -3.03 | -3.48 | -4.31 | -4.76 |
| Normalized Diluted EPS | -1.47 | -1.87 | -2.07 | -2.60 | -2.88 |
| Average Basic Shares Outstanding | 40.29M | 28.72M | 19.21M | 10.97M | 7.95M |
| Average Diluted Shares Outstanding | 40.29M | 28.72M | 19.21M | 10.97M | 7.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |